Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1/2 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced metabolic stability and liver distribution that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-801 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Future Catalysts | Upcoming trial results and potential partnerships could significantly impact stock performance, with analyst price targets ranging from $15 to $20 |
Market Dynamics | Explore how Terns navigates competitive CML and obesity treatment landscapes, with analysts noting potential for significant market share capture |
Financial Health | Strong cash position of $315 million provides runway into 2028, supporting ongoing clinical trials without immediate financing concerns |
Promising Pipeline | Terns Pharmaceuticals' TERN-701 for CML and TERN-601 for obesity show potential to disrupt markets, with key data readouts expected in Q4 2025 |
Metrics to compare | TERN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTERNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −63.3x | −8.1x | −0.5x | |
PEG Ratio | −8.33 | −0.11 | 0.00 | |
Price / Book | 6.1x | 4.2x | 2.6x | |
Price / LTM Sales | - | 7.0x | 3.2x | |
Upside (Analyst Target) | 0.5% | 47.8% | 47.6% | |
Fair Value Upside | Unlock | 6.4% | 6.1% | Unlock |